Characteristics of the Matched Patients (PRD, PSD, and R1) Included in the Risk-Factor Analysis for Second Cancer (External Analysis)
| . | Grafted Patients (n = 393) . | Nongrafted Patients (n = 1,179) . | P Value . |
|---|---|---|---|
| Age at diagnosis (range) Age ≥40 at diagnosis | 29 (8-58) 19% | 29 (14-60) 19% | .75 .97 |
| Gender (M/F) | 62%/38% | 62%/38% | 1.0 |
| Stage I-II III-IV | 37% 63% | 37% 63% | 1.0 |
| B symptoms | 71% | 71% | 1.0 |
| Diagnosis time 1970-79 1980-89 1990-95 | 0% 35% 65% | 48% 43% 9% | <.001 |
| Cumulative treatment Splenectomy Radiotherapy No Limited field Extended field Chemotherapy No ≥3 MOPP <3 MOPP Adriamycin containing Others | 10% 21% 37% 42% 0% 21% 58% 18% 3% | 32% 39% 34% 27% 12% 79% 4% 1% 4% | <.001 <0.001 <.001 <.001 |
| Median follow up from end of last treat ment (range) | 21 mo (1-130) | 31 mo (1-209) | <.001 |
| Deaths | 33% | 44% | <.001 |
| Cause of death Hodgkin’s disease Toxicity Intercurrent disease Second cancer Unknown | 72% 22% 1% 5% 0% | 83% 5% 6% 5% 1% | <.001 |
| . | Grafted Patients (n = 393) . | Nongrafted Patients (n = 1,179) . | P Value . |
|---|---|---|---|
| Age at diagnosis (range) Age ≥40 at diagnosis | 29 (8-58) 19% | 29 (14-60) 19% | .75 .97 |
| Gender (M/F) | 62%/38% | 62%/38% | 1.0 |
| Stage I-II III-IV | 37% 63% | 37% 63% | 1.0 |
| B symptoms | 71% | 71% | 1.0 |
| Diagnosis time 1970-79 1980-89 1990-95 | 0% 35% 65% | 48% 43% 9% | <.001 |
| Cumulative treatment Splenectomy Radiotherapy No Limited field Extended field Chemotherapy No ≥3 MOPP <3 MOPP Adriamycin containing Others | 10% 21% 37% 42% 0% 21% 58% 18% 3% | 32% 39% 34% 27% 12% 79% 4% 1% 4% | <.001 <0.001 <.001 <.001 |
| Median follow up from end of last treat ment (range) | 21 mo (1-130) | 31 mo (1-209) | <.001 |
| Deaths | 33% | 44% | <.001 |
| Cause of death Hodgkin’s disease Toxicity Intercurrent disease Second cancer Unknown | 72% 22% 1% 5% 0% | 83% 5% 6% 5% 1% | <.001 |